EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

De Novo Designed Minibinders Targeting the GDF15–GFRAL Axis Reverse Cancer Cachexia and Restore Anti‐Tumor Immunity

Haitao Wang, Tianzhen Hua, Meiling Wang, Bingbing Meng, Yue Zhang, Chengxu Jiang, Yunhe Gao, Hongqi Yang, Jian Bo iD

Advanced Science · 2026-09 · 13 (51)

DOI: 10.1002/advs.76202 ↗

At a glance

Journal article in Advanced Science, published online on 2026-07-07. Written by Haitao Wang and 8 co-authors. Institution: Senior Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China. Major MEDLINE topics: Cachexia, Growth Differentiation Factor 15, Neoplasms. Cited 1 times so far (Crossref); 36 references. The full text is freely available (open access, CC BY 4.0). Funded by: Major Logistics Project of the Chinese People's Liberation Army, Innovation Transcend Project of National Defense Science and Technology, Key Logistics Project of the Chinese People's Liberation Army.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Cancer‐associated cachexia is a devastating syndrome characterized by progressive weight loss, reduced survival, and impaired responses to anticancer therapies. Growth differentiation factor 15 (GDF15), acting through its receptor GFRAL, has emerged as a key mediator of cachexia, yet effective and mechanistically defined strategies to neutralize this pathway remain limited. Here, we applied structure‐guided de novo protein design to generate compact minibinders that selectively target the GDF15–GFRAL interaction interface. Using an integrated computational pipeline combining RFdiffusion, ProteinMPNN, and AlphaFold 3 structure prediction, we designed and experimentally validated high‐affinity GDF15 minibinders with picomolar‐range binding affinities and exceptional structural stability. Mutagenesis and charge‐complementary rescue experiments confirm that these minibinders neutralize GDF15 through precisely engineered interface contacts. Functionally, the minibinders suppress GDF15–GFRAL signaling, inhibit downstream transcriptional responses, and robustly reverse cachexia in vivo across multiple tumor models, resulting in significant improvements in body weight and survival. Importantly, neutralization of GDF15 also restores sensitivity to anti–PD‐1 immunotherapy in a GDF15‐driven resistant tumor model. Combination treatment enhances CD8 + T cell infiltration and effector function within tumors, and its antitumor efficacy is strictly dependent on CD8 + T cells. Together, these findings demonstrate that de novo designed GDF15 minibinders can achieve potent, mechanism‐defined neutralization of the GDF15–GFRAL axis in vivo, translating into robust physiological benefits and restoration of immunotherapy efficacy.

Subjects

MeSH terms (MEDLINE)

CachexiaGrowth Differentiation Factor 15NeoplasmsAnimalsMiceHumansSignal Transduction

Author keywords

GDF15RFdiffusioncancer cachexiade novo protein designimmune checkpoint blockade

Substances

Growth Differentiation Factor 15GDF15 protein, human

Authors and institutions

  • Senior Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Chinese PLA Medical School, Beijing, China.
  • Naval Medical University, Shanghai, China.
  • University of Montpellier, Montpellier, France.
  • Senior Department of General Surgery, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Department of Emergency, The Second Medical Center of Chinese PLA General Hospital, Beijing, China.

ORCID profiles: Jian Bo

Funding

  • Major Logistics Project of the Chinese People's Liberation Army
  • Innovation Transcend Project of National Defense Science and Technology
  • Key Logistics Project of the Chinese People's Liberation Army
  • Beijing Natural Science Foundation
  • Postdoctoral Fellowship Program of CPSF
  • Natural Science Foundation of Beijing Municipality

Cite

APA

Wang, H., Hua, T., Wang, M., Meng, B., Zhang, Y., Jiang, C., Gao, Y., Yang, H., & Bo, J. (2026). De Novo Designed Minibinders Targeting the GDF15–GFRAL Axis Reverse Cancer Cachexia and Restore Anti‐Tumor Immunity. Advanced Science, 13(51). https://doi.org/10.1002/advs.76202

Vancouver

Wang H, Hua T, Wang M, Meng B, Zhang Y, Jiang C, et al. De Novo Designed Minibinders Targeting the GDF15–GFRAL Axis Reverse Cancer Cachexia and Restore Anti‐Tumor Immunity. Advanced Science. 2026;13(51). doi:10.1002/advs.76202

BibTeX
@article{Wang2026,
  author = {Wang, Haitao and Hua, Tianzhen and Wang, Meiling and Meng, Bingbing and Zhang, Yue and Jiang, Chengxu and Gao, Yunhe and Yang, Hongqi and Bo, Jian},
  title = {De Novo Designed Minibinders Targeting the GDF15–GFRAL Axis Reverse Cancer Cachexia and Restore Anti‐Tumor Immunity},
  journal = {Advanced Science},
  year = {2026},
  volume = {13},
  number = {51},
  doi = {10.1002/advs.76202}
}
Start for free →